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ARTICLE OPEN
Diagnostic accuracy of pre-bronchodilator FEV1/FEV6 from
microspirometry to detect airﬂow obstruction in primary care:
a randomised cross-sectional study
Lisette van den Bemt1, Bram CW Wouters1, Joke Grootens1, Joke Denis2, Patrick J Poels1 and Tjard R Schermer1
BACKGROUND: Forced expiratory volume in 1s/forced expiratory volume in 6 s ( FEV1/FEV6) assessment with a microspirometer
may be useful in the diagnostic work up of subjects who are suspected of having COPD in primary care.
AIM: To determine the diagnostic accuracy of a negative pre-bronchodilator (BD) microspirometry test relative to a full diagnostic
spirometry test in subjects in whom general practitioners (GPs) suspect airﬂow obstruction.
METHODS: Cross-sectional study in which the order of microspirometry and diagnostic spirometry tests was randomised. Study
subjects were (ex-)smokers aged ⩾ 50 years referred for diagnostic spirometry to a primary care diagnostic centre by their GPs.
A pre-BD FEV1/FEV6 value o0.73 as measured with the PiKo-6 microspirometer was compared with a post-BD FEV1/FVC (forced
vital capacity) o0.70 and FEV1/FVCo lower limit of normal (LLN) from diagnostic spirometry.
RESULTS: One hundred and four subjects were analysed (59.6% males, 42.3% current smokers). Negative predictive values from
microspirometry for airﬂow obstruction based on the ﬁxed and LLN cut-off points were 94.4% (95% conﬁdence interval (CI),
86.4–98.5) and 96.3% (95% CI, 88.2–99.3), respectively. In all, 18% of positive microspirometry results were not conﬁrmed by a post-
BD FEV1/FVC o0.70 and 44% of tests were false positive compared with the LLN criterion for airﬂow obstruction.
CONCLUSIONS: Pre-bronchodilator microspirometry seems to be able to reliably preselect patients for further assessment of
airﬂow obstruction by means of regular diagnostic spirometry. However, use of microspirometry alone would result in
overestimation of airﬂow obstruction and should not replace regular spirometry when diagnosing COPD in primary care.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is widely under-
diagnosed in primary care.1–4 The hallmark of COPD is
chronic airﬂow obstruction objectiﬁed by spirometry after the
administration of a bronchodilator (BD).5 High-quality spirometry
requires extensive training of staff, reliable equipment and well-
standardised measurement procedures.6,7 Although the majority
of general practitioners (GPs) recognise the importance of
conﬁrmatory spirometry testing when diagnosing COPD, it is still
underutilised.8 According to GPs, inability to apply spirometry
during consultation is an important barrier.8
Diagnostic spirometry requires measurement of the ratio of
forced expiratory volume in 1 s (FEV1) and forced vital capcity
(FVC) in order to calculate the FEV1/FVC ratio, which is the main
diagnostic criterion for COPD. Forced expiratory volume in 6 s
(FEV6) can be used as a valid surrogate for FVC
9 and is less prone
to measurement error.10
Simple hand-held microspirometers such as the PiKo-6 (nSpire
Health Inc., Longmont, CO, USA) and COPD6 (Vitalograph Ltd,
Ennis, Ireland) can be used to measure the FEV1/FEV6 ratio. Results
of previous studies indicate that these devices are effective and
reliable screening tools that can reduce underdiagnosis of COPD
in primary care.11,12 A pre-BD FEV1/FEV6 assessment takes little
time and has the potential to be integrated into a GP's ofﬁce
consultations, which is not the case with a full (pre- and post-BD)
spirometry test. On the basis of microspirometry test results,
candidates for further diagnostic spirometric assessment can be
selected, which could reduce underdiagnosis of COPD and at the
same time increase the efﬁciency of full diagnostic spirometry use
in primary care. However, this will only be the case when a
negative (i.e., normal) pre-BD FEV1/FEV6 value from a microspiro-
metry test rules out the presence of airﬂow obstruction with
sufﬁcient certainty.
The aim of this study was to determine the diagnostic accuracy
of a pre-BD FEV1/FEV6 ratio from microspirometry relative to a
post-BD FEV1/FVC ratio from a diagnostic spirometry test in
patients referred for spirometry by GPs because of respiratory
symptoms that may suggest underlying COPD. Because we focus
on the potential role of microspirometry to select patients for
further diagnostic spirometry testing, we were especially inter-
ested in the negative predicted value of a normal microspirometry
result.
MATERIALS AND METHODS
Study design and subjects
A randomised cross-sectional diagnostic study was set up at the ‘Stichting
Huisartsen Laboratorium’ (SHL), a regional primary care diagnostic centre
that performs diagnostic spirometry tests at several sites for general
practitioners (GPs) in the South-Western part of the Netherlands.
Participants were recruited from among individuals who visited the
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diagnostic centre for a diagnostic spirometric test based on a referral by
their GP for respiratory symptoms that may suggest underlying COPD. We
included subjects who were 50 years or older and who were current or
former smokers (⩾1 pack year). Exclusion criteria were: (1) refusal or
inability to give informed consent; (2) having undergone a spirometry test
in the previous 5 years; (3) having already been diagnosed with COPD; and
(4) anticipated inability to perform 12 forced blows as presumed by the
lung function technician.
The study was conducted between October 2010 and January 2012.
According to the medical ethics review board of the Radboud University
Medical Centre, the study was exempted from ethics review (ﬁle number
2010/286). All participants gave written informed consent before any study
procedure took place.
Study procedures
All participants underwent diagnostic spirometry and a microspirometry
test before and after administration of 400 μg of aerosolised salbutamol by
means of a Volumatic spacer, all during the same visit to the diagnostic
centre. The order of diagnostic spirometry and microspirometry testing
was randomised. Participating sites of the diagnostic centre received
sealed envelopes with the randomisation code. Subjects had to start with
either microspirometry or the diagnostic spirometry test before as well as
after the administration of the BD, which resulted in the following two
possible test sequences:
(1) pre-BD microspirometry–pre-BD spirometry–post-BD microspirometry-
–post-BD spirometry; or
(2) pre-BD spirometry–pre-BD microspirometry–post-BD spirometry–
post-BD microspirometry
Following the diagnostic centre’s protocol, all tests were performed at
least 12 h after the last inhalation of a short-acting BD or a long-acting
beta-2-agonist, and at least 72 h after inhalation of tiotropium.
Microspirometry
Microspirometry testing was performed by trained lung function staff who
were given a uniform and brief training on how to use the PiKo-6
according to the manufacturer’s instructions. PiKo-6 devices were checked
for calibration errors before the start of the study by the investigators.
Subjects were required to inhale maximally, and exhale as hard and as
fast as possible into the mouthpiece of the PiKo-6 until an end-of-test beep
was heard after 6 s. At least three valid attempts were taken before and
after the administration of the BD. The PiKo-6 has an automatic test quality
alert and indicates attempts that were invalid because of coughing or
abnormal blow. The highest FEV1 and FEV6 value of the three pre-BD
measurements were used (which were not necessarily from the same
blow) and the FEV1/FEV6 ratio was calculated. We used a ﬁxed FEV1/FEV6
cut-off point of o0.73 as an indicator for airﬂow obstruction, which was
shown to be a valid alternative to FEV1/FVC o0.70 in previous studies.13,14
Diagnostic spirometry
Diagnostic spirometry testing was performed by the same lung function
technicians, using the PC-based SpiroPerfect spirometer (Welch Allyn,
New York, NY, USA). The spirometer was calibrated each day before testing
started. The spirometric tests had to meet the recommendations of the
ATS/ERS guidelines.15 At least three reproducible blows of good quality
were taken for pre-BD and post-BD measurements. The post-BD
measurement with the highest FEV1/FVC ratio was recorded and used
for analysis. The lower limit of normal (LLN) values used for analysis were
calculated using the 2012 Global Lungs Initiative (GLI-2012) spirometric
prediction equations.16
Questionnaire
Participants ﬁlled out a questionnaire about possible previous diagnoses of
chronic respiratory conditions, cigarette smoking, respiratory medication
use, previous spirometry tests and reason for referral by the GP. During the
waiting time between the pre- and post-BD tests, demographic and
disease-speciﬁc information (e.g., respiratory symptoms and exacerbations)
were inquired in a standardised way by the lung function technician.
Outcomes, sample size and analysis
The main outcome of interest for the study was the negative predictive value
(NPV) of a pre-BD FEV1/FEV6 value o0.73 as measured with the PiKo-6
microspirometer compared with a post-BD FEV1/FVC value o0.70 from a
diagnostic spirometry test, the latter serving as the gold standard. Positive
predictive value, sensitivity and speciﬁcity of a pre-BD FEV1/FEV6 value o0.73
were also analysed. The same calculations were made with a post-BD
FEV1/FVC oLLN from diagnostic spirometry as an alternative gold standard.17
Sample size was chosen to be able to demonstrate an NPV of 95%, for
microspirometry with a lower conﬁdence limit of 90%. Earlier research
showed a prevalence of 12–30% of undiagnosed COPD in male smokers
aged 40 years and over.18 However, because of the inclusion criteria the
subjects in our study would be older and all would have respiratory
symptoms. Therefore, we assumed a 35% prevalence of undetected airﬂow
obstruction in subjects referred for spirometry by their GP. With the
aforementioned assumptions, we calculated a sample size of n= 112. Given
the cross-sectional design of the study, no drop-outs were expected.
Descriptive statistics (numbers (%)) were used to describe the study
population’s characteristics. The diagnostic accuracy measures (i.e., NPV,
positive predictive value, speciﬁcity and sensitivity) were calculated using
crosstabs, and 95% conﬁdence interval (CI) were determined. Kappa statistics
for agreement between pre-BD FEV1/FEV6 and post-BD FEV1/FVC cut-off
points were also calculated. Moreover, a receiver operating characteristic
curve and its area under the curve were calculated, with post-BD FEV1/
FVCo0.7 as the gold standard for chronic airﬂow obstruction.
Not all subjects were referred speciﬁcally for suspected COPD. In some
cases, the GP’s referral indication for the diagnostic spirometry test was
asthma or reasons less clear (e.g., ‘dyspnoea’ or ‘chronic cough’). Therefore,
a sub-analysis was conducted with the subjects who had been referred for
spirometry by their GP speciﬁcally for evaluation of possible underlying
COPD. Statistical analyses were performed using IBM SPSS software
(Chicago, IL, USA, version 20).
RESULTS
Study population
A total of 121 subjects were recruited (see Figure 1), of whom 111
subjects were eligible for the study. Of them, six failed to complete
Subjects recruited
(n =121)
Subjects eligible for study
(n =111)
Subjects in analyses
(n =104)*
Subjects in subgroup
analyses COPD only
(n =55)
Not eligible (n =10)
- Never smoked (n =2)
- Already diagnosed with COPD (n =5)
- Spirometry < 5 yrs (n =3)
Excluded (n =7)
- PiKo-6 test incomplete (n =6)
- Spirometry data incomplete (n =1)
* Violation of randomisation sequence (n =3)
Figure 1. Flow chart of subject recruitment and selection.
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the microspirometry test, and diagnostic spirometry data were
incomplete for one patient. Valid diagnostic spirometry and
microspirometry data were available for 104 study participants.
Table 1 shows baseline and clinical characteristics of the subjects.
Airﬂow obstruction (i.e., post-BD FEV1/FVC o0.7) was observed in
44 subjects (42.3%), with most of them (88.6%) being classiﬁed
as having mild to moderate airﬂow obstruction (see Table 1).
Forty-three per cent of subjects with no airﬂow obstruction used
prescribed respiratory medication. Twelve subjects (11.5%) met
the criteria for a reversible airﬂow obstruction.
Diagnostic accuracy of pre-BD FEV1/FEV6 ratio o0.73
Of the 54 subjects with a negative microspirometry test (i.e.,
pre-BD FEV1/FEV6 ⩾ 0.73), absence of airﬂow obstruction was
conﬁrmed by a negative diagnostic spirometric test (i.e., post-BD
FEV1/FVC ⩾ 0.70) in 51 subjects (see Figure 2). Thus, the NPV was
94.4% (95% CI, 86.4–98.5). Table 2 shows the diagnostic test
characteristics both (i.e., ⩾ 0.73 and ⩾ LLN) for the diagnostic
spirometry cut-off points and for the subgroup of subjects with a
speciﬁc referral for suspected COPD. The NPV of pre-BD FEV1/FEV6
⩾ 0.73 was high for both deﬁnitions of airﬂow obstruction but with
96.3% (95% CI, 88.2–99.3) slightly better for the LLN cut-off point.
The NPV for subjects referred speciﬁcally for suspected COPD was
96.3% for both diagnostic spirometry cut-off points. Positive
microspirometry tests were conﬁrmed by positive diagnostic
spirometry tests in only 82.0% (95% CI, 73.3–86.3) and 56.0%
(95% CI, 47.3–59.3), respectively (see Table 2 for these positive
predictive values and the results for speciﬁcity, sensitivity and
Kappa). Figure 3 shows the receiver operating characteristic curve
for different FEV1/FEV6 cut-off points. The area under the curve
was 0.937.
DISCUSSION
Main ﬁndings
This study shows that the use of microspirometry seems to be a
method for preselecting subjects for further diagnostic spirometry
testing in the diagnostic work up of patients who, according to
their GP, may have chronic airﬂow obstruction. Taking into
account that the NPV of microspirometry was 94.4%, a subject
with a negative microspirometry test (pre-BD FEV1/FEV6 ⩾ 0.73) is
rather unlikely to show airﬂow obstruction in a subsequent
diagnostic spirometry test and thus to have COPD. On the other
hand, 18% of subjects with a positive microspirometry test (i.e.,
pre-BD FEV1/FEV6 o0.73) had no airﬂow obstruction (post-BD
FEV1/FCV 40.70) according to diagnostic spirometric assessment
and 44% of these subjects did not fulﬁl the LLN criterion for
airﬂow obstruction. This illustrates that (pre-BD) microspirometry
should not be used to diagnose COPD.
Strengths and limitations of this study
In our study the test sequence was randomised and therefore, the
effect of possible fatigue and learning effect of previous blows
was minimised. However, in three subjects the randomisation
sequence was violated. Data of these subjects were used for
analysis as the effect of this protocol violation was considered
negligible.
The ﬁxed post-BD o0.70 FEV1/FVC cut-off is a widely accepted
criterion to deﬁne airﬂow obstruction in COPD.5 As FEV1 decreases
more quickly with age than does FVC, this criterion tends to
overdiagnose COPD in the elderly.19,20 Therefore, some studies
have suggested the use of LLN to deﬁne airﬂow obstruction when
diagnosing COPD.21 The LLN is based on patient characteristics
(age, height and race) and an FEV1/FVC value below the lower ﬁfth
percentile of an appropriate healthy reference group is considered
abnormal. Given the changing perception of how to detect airﬂow
obstruction, we also used the LLN as a gold standard diagnostic
spirometry outcome to validate the FEV1/FEV6 ratio from
Table 1. Characteristics of the study sample (n= 104)
Characteristic Number %
Male 62 59.6
Age group
50–59 years 42 40.4
60–69 years 51 49.0
⩾ 70 years 11 10.6
Current smokersa 44 42.3
Packyearsb
1–14 32 30.8
15–30 32 30.8
⩾ 30 39 37.5
Reason to refer for spirometry
COPD 55 52.9
Asthma 16 15.4
Asthma/COPD 5 4.8
Otherc 11 10.6
None mentioned 17 16.3
Post-BD FEV1/FVCo0.70 44 42.3
Severity of airﬂow obstruction
Mild (FEV1 ⩾ 80% predicted) 22 50
Moderate (50% ⩽ FEV1o80% predicted) 17 38.6
Severe (30% ⩽ FEV1o50% predicted) 5 11.4
Reversible airﬂow obstructiond 12 11.5
Use of respiratory medicationa
Short-acting bronchodilators 25 24.5
Long-acting bronchodilators 11 10.8
Inhaled corticosteroids 15 14.7
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in 1 s; FVC, forced vital capacity.
aTwo missing.
bOne missing.
cOther: three referred on account of dyspnoea, three for coughing and
sputum production and ﬁve for an unspeciﬁed diagnostic referral for
spirometry.
dPost-BD FEV1 12% and 200ml higher compared with pre-BD FEV1.
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Figure 2. Scatter plot of pre-bronchodilator FEV1/FEV6 from micro-
spirometry against post-bronchodilator FEV1/FVC from diagnostic
spirometry.
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microspirometry. The analyses based on LLN showed slightly
higher NPVs (96.3%) compared with the ﬁxed cut-off value
(94.4%).
Subjects were referred for diagnostic spirometry by their GPs.
As shown, there were several reasons for referral, of which the
largest part (n= 55/104) consisted of ‘COPD’. ‘Asthma’ or ‘asthma/
COPD’ were other recurring indications for referral (n= 21). For GPs
it is difﬁcult to differentiate between COPD and asthma, given the
signiﬁcant overlap in the clinical presentation of these two
conditions.22,23 Therefore, all subjects were included in the main
analysis regardless of the indication as written on the referral form.
The NPVs of the subgroup analyses with patients referred for
COPD only were very similar to the NPVs when all subjects were
included, indicating that this was a valid approach.
A limitation of a PiKo-6 test is that it displays the highest FEV1
and FEV6 of a set of attempts that are not necessarily reproducible.
Therefore, any outliers in these values may inﬂuence the results
for an individual substantially. In fact, 19% of PiKo-6 tests (i.e.,
three valid attempts) failed to fulﬁl the criteria for reproducibility
for the pre-BD FEV1 value and 34% failed to fulﬁl the criteria for
the reproducibility of the pre-BD FEV6 value.
15 This is another
good reason why a full spirometric exam remains essential to
conﬁrm a diagnosis of COPD.
In this study we did not look at the validity (i.e., accuracy and
precision) of the PiKo-6 device itself, and to our knowledge there
are no published reports about the validity of this particular
device. Moreover, different types or brands of microspirometers
may differ in terms of their accuracy and precision for the FEV1
and FEV6 values they measure. Therefore our observations in the
current study cannot be extrapolated to other devices than the
PiKo-6.
A ﬁnal limitation is the fact that we did not have information on
the quality and reproducibility of the full spirometric test as well.
The diagnostic centre was used to save only the best FEV1 and
FVC value in their database, and therefore we have to rely on the
professional judgement of the lung function staff of the primary
care diagnostic centre.
Interpretation of ﬁndings in relation to previously published work
Previous studies have suggested different cut-off points for the
FEV1/FEV6 ratio (i.e., o0.75,9 o0.808 and o0.7024,25 to detect
airﬂow obstruction in primary care settings. In our study, we used
the cut-off point of o0.73, which has been recommended as the
preferred alternative for FEV1/FVC o0.70.9,13,26 It is to be
expected that a higher FEV1/FEV6 cut-off point decreases the
number of false-negative results and increases the number of
false-positive results. This was also the case in our study: at a cut-
off FEV1/FEV6 ratio o0.75 the NPV would have been 97.8% and
the positive predictive value 72.9% (instead of 94.4% and 82.0%,
respectively).
In previous studies, the study population consisted of current
and former smokers aged ⩾ 40, ⩾ 45 or ⩾ 50 years.11,12,19,26 In our
current study, subjects were referred by their GP for spirometry
testing because of respiratory symptoms that could suggest
underlying COPD in addition to being at risk on the basis of age
and smoking history. This might explain the high prevalence of
spirometry-conﬁrmed airﬂow obstruction in our study (44.4%)
compared with previous studies.11,12,19,26
Moreover, previous studies focused on the sensitivity and
speciﬁcity of microspirometry. We speciﬁcally looked at the NPV as
the primary outcome. In our view NPV best reﬂects the purpose
that microspirometry can have in primary care: to preselect
candidates for full diagnostic spirometry in order to avoid
unnecessary testing. In our study, the NPV of the pre-BD
FEV1/FEV6 ratio from microspirometry was slightly different from
the NPVs reported by Sichletidis et al.24 and Frith et al.,12 who
reported NPV values of 98% and 91%, respectively. Both values are
within the 95% CI (86.4–98.5) of the NPV that we found in our
study. The main difference of the study by Sichletidis and
Table 2. Diagnostic test characteristics of pre-BD FEV1/FEV6 o0.73 values from microspirometry versus post-BD FEV1/FVC from diagnostic
spirometry for different cut-off points
Cut-off point All subjects (n= 104) Subjects referred for COPD (n= 55)
o0.70 oLLN o0.70 oLLN
NPV (95% CI) 94.4 (86.4–98.5) 96.3 (88.2–99.3) 96.3 (88.3–99.8) 96.3 (83.1–99.8)
PPV (95% CI) 82.0 (73.3–86.3) 56.0 (47.3–59.3) 78.6 (66.1–82.0) 57.1 (44.4–60.5)
Sensitivity (95% CI) 93.2 (83.3–98.1) 93.3 (78.8–98.8) 95.7 (80.4–99.8) 94.4 (73.1–99.7)
Speciﬁcity (95% CI) 85.0 (77.8–88.6) 70.3 (64.4–72.5) 81.3 (70.3–84.2) 68.4 (59.0–70.9)
Kappa 0.77 (0.60–0.85) 0.53 (0.36–0.60) 0.75 (0.49–0.82) 0.53 (0.27–0.60)
Abbreviations: FEV1, forced expiratory volume in 1 s; FEV6, forced expiratory volume in 6 s; FVC, forced vital capacity; LLN, lower limit of normal; NPV, negative
predictive value; PPV, positive predictive value.
Estimates are shown with 95% conﬁdence intervals in parentheses.
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Figure 3. Receiver operating characteristic (ROC) curve and its
coordinates for the forced expiratory volume in 1 s /forced
expiratory volume in 6 s (FEV1/FEV6) ratio using post-BD
FEV1/FVCo0.7 as criterion for chronic airﬂow obstruction
(AUC: 0.937).
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co-workers compared with our study is their use of post-BD
FEV1/FEV6 microspirometry values, which may be expected to
correlate better with the post-BD FEV1/FVC value, but is less
practical than using a pre-BD test. Dissimilarities with the study
by Frith et al. are the aforementioned differences in subject
recruitment.
Implications for future research and practice
This is the ﬁrst validation study to determine the diagnostic
accuracy of a hand-held microspirometer in subjects with clinically
suspected airﬂow obstruction that point to underlying COPD in a
primary care setting. Given the ﬁndings from this study, a
microspirometer could provide GPs with a simple and reliable
method to preselect patients for full diagnostic spirometry. The
simplicity of a microspirometer ﬁts into the tight work schedule of
GPs during ofﬁce consultations. However, one question that
remains is whether the same diagnostic test characteristics are
obtained when microspirometry is performed in primary care
practices by GPs themselves. Thorn et al. found that FEV1/FEV6
assessment (with a COPD6) by asthma/COPD nurses in primary
care practices had acceptable sensitivity and speciﬁcity, although
the test characteristics were not as good as in our study.26
Furthermore, microspirometers have the potential to optimise
early referral for spirometry and may facilitate early, targeted
interventions aimed at reducing the burden of COPD. The
effectiveness of such interventions needs to be evaluated as well,
as robust evidence on this issue is currently lacking. However,
based on the high percentage of patients that will be
misdiagnosed with COPD when such a device is used only (with
a cut-off o0.73), conﬁrmative diagnostic spirometry remains
essential. A false-positive microspirometry test could be the result
of reversible airﬂow obstruction (i.e., the hallmark of asthma).
Therefore, there might be a positive ‘side-effect’ of microspiro-
metry that warrants further study as well, although pre-BD
microspirometry cannot rule out asthma and should not be used
to preselect patients at risk for asthma.
Conclusions
Pre-BD microspirometry seems to be a valid method to preselect
subjects for full diagnostic spirometry in the diagnostic work up of
subjects who are suspected of having COPD in primary care.
However, microspirometry should not replace regular diagnostic
spirometry.
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